Drug General Information |
Drug ID |
D0V0KA
|
Former ID |
DIB019356
|
Drug Name |
compound 22
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
|
Formula |
C20H18ClN3O2
|
InChI |
InChI=1S/C20H18ClN3O2/c21-16-11-15-13(8-9-22-19(15)25)10-17(16)24-20(26)18(23-14-6-7-14)12-4-2-1-3-5-12/h1-5,8-11,14,18,23H,6-7H2,(H,22,25)(H,24,26)
|
InChIKey |
SKYALJGMRAGHEN-UHFFFAOYSA-N
|
PubChem Compound ID |
|
PubChem Substance ID |
|
Target and Pathway |
Target(s) |
Rho-associated protein kinase 1 |
Target Info |
Inhibitor |
[1]
|
NIMA-related kinase 7 |
Target Info |
Inhibitor |
[1]
|
Rho associated protein kinase 2 |
Target Info |
Inhibitor |
[1]
|
NIMA-related kinase 6 |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
cGMP-PKG signaling pathway
|
cAMP signaling pathway
|
Chemokine signaling pathway
|
Sphingolipid signaling pathway
|
Vascular smooth muscle contraction
|
TGF-beta signaling pathway
|
Axon guidance
|
Focal adhesion
|
Platelet activation
|
Leukocyte transendothelial migration
|
Regulation of actin cytoskeleton
|
Oxytocin signaling pathway
|
Pathogenic Escherichia coli infection
|
Shigellosis
|
Salmonella infection
|
Pathways in cancer
|
Proteoglycans in cancer
|
MicroRNAs in cancerhsa04022:cGMP-PKG signaling pathway
|
Wnt signaling pathway
|
PANTHER Pathway
|
Cytoskeletal regulation by Rho GTPase
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
CCKR signaling map STP00016:Cytoskeletal regulation by Rho GTPase
|
Pathway Interaction Database
|
Signaling events mediated by PRL
|
RhoA signaling pathway
|
Noncanonical Wnt signaling pathway
|
EPHB forward signaling
|
Thromboxane A2 receptor signaling
|
PAR4-mediated thrombin signaling events
|
amb2 Integrin signaling
|
Integrins in angiogenesis
|
EPHA forward signaling
|
Stabilization and expansion of the E-cadherin adherens junction
|
Signaling events mediated by VEGFR1 and VEGFR2
|
PAR1-mediated thrombin signaling events
|
N-cadherin signaling eventsrhoa_pathway:RhoA signaling pathway
|
Plasma membrane estrogen receptor signaling
|
Osteopontin-mediated events
|
PLK1 signaling events
|
Signaling events mediated by focal adhesion kinase
|
Reactome
|
Apoptotic cleavage of cellular proteins
|
EPHB-mediated forward signaling
|
EPHA-mediated growth cone collapse
|
G alpha (12/13) signalling events
|
Sema4D induced cell migration and growth-cone collapse
|
VEGFA-VEGFR2 Pathway
|
RHO GTPases Activate ROCKsR-HSA-3928662:EPHB-mediated forward signaling
|
RHO GTPases Activate ROCKs
|
WikiPathways
|
G13 Signaling Pathway
|
Regulation of Actin Cytoskeleton
|
EGF/EGFR Signaling Pathway
|
TGF beta Signaling Pathway
|
Focal Adhesion
|
JAK/STAT
|
AGE/RAGE pathway
|
Pathogenic Escherichia coli infection
|
Regulation of Microtubule Cytoskeleton
|
Leptin signaling pathway
|
Semaphorin interactions
|
Integrin-mediated Cell Adhesion
|
GPCR downstream signaling
|
Apoptotic execution phase
|
MicroRNAs in cardiomyocyte hypertrophy
|
Androgen receptor signaling pathwayWP524:G13 Signaling Pathway
|
Spinal Cord Injury
|
Androgen receptor signaling pathway
|
References |
REF 1 | Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3235-9. |